The Hormone Pipeline: DHEA, Aromatization, and the Aromatase Trap

You hit your forties and something shifts. Not dramatically — not overnight — but gradually, unmistakably. Energy that used to be on tap starts requiring more effort to access. Recovery takes longer. Mood swings in directions it never used to. Body composition changes in ways that diet and training can’t fully explain. You’re not imagining it. Your hormone pipeline is changing — and the most important molecule most people have never heard of is at the center of it. Enter DHEA, and the conversion trap that catches even the most research-savvy people completely off guard.

This is Part 2 of our Biological Age series. In Part 1, we examined the TRIIM trial’s landmark evidence that biological age can be reversed — and DHEA was one of the three agents at the center of that protocol. Now it’s time to understand why DHEA was included, what it actually does inside the body, and why the conventional wisdom of “just take more” can send you in exactly the wrong direction.

KYLE HANSEN FITNESS

Part 2 of 3: The Biological Age Series

Adrenopause: The Hormonal Shift No One Talks About

Most people know about menopause. A growing number know about andropause — the gradual decline in testosterone that affects men in their forties and beyond. But there is a third hormonal transition happening in both men and women that rarely gets a headline: adrenopause.

Adrenopause affects everyone with adrenal glands, which is everyone. No exceptions based on sex, fitness level, or lifestyle.

DHEA is their highest-volume output by a wide margin. At peak production in your mid-twenties, your adrenal plant is running at full capacity. By the time most people reach 70, DHEA output has dropped to roughly 10 to 20 percent of that peak.¹

The downstream consequences aren’t obvious in isolation. DHEA doesn’t act directly on tissues the way testosterone or estrogen do. Its effects are upstream — as the raw material from which the body manufactures the hormones that do act directly. Decline the raw material supply, and production of the downstream products eventually follows.

Adrenopause isn’t a disease. It’s a biological reality that begins before most people are paying attention — and it affects men and women equally.

Who Feels Adrenopause Most Acutely?

While adrenopause is universal, the experience of it varies significantly based on how dependent your system is on adrenal androgens for hormonal balance. Several groups tend to feel the shift most clearly:

• Men in their 40s and 50s whose testosterone is simultaneously declining through andropause — the DHEA drop compounds a system already under hormonal pressure.
• Women post-menopause, for whom adrenal DHEA becomes the primary remaining androgen source once ovarian production ceases. Libido, energy, bone density, and cognitive sharpness all have DHEA-dependent components.
• Anyone under chronic stress — cortisol and DHEA share a precursor molecule (pregnenolone). When your stress response is chronically activated and cortisol production is high, it competes for that upstream raw material, further depressing DHEA output. This is the hormonal equivalent of your factory diverting its supply chain entirely to one product line and shutting down the others.
• Individuals with adrenal insufficiency — in clinical populations where the adrenal glands are compromised, DHEA replacement is not experimental but standard of care, with solid evidence for improvements in well-being, energy, and libido.¹

The premise of DHEA replacement — as used in the TRIIM trial — is built on this reality: if the body’s own production is no longer sufficient to support healthy downstream hormone levels, providing an exogenous source of the raw material may restore that capacity. That sounds straightforward. It isn’t.

DHEA as a Prohormone: Raw Material, Not End Product

Here’s where the science gets more nuanced than most DHEA marketing suggests — and where understanding the mechanism matters more than reading the label.

DHEA is a prohormone — dehydroepiandrosterone — meaning it is not a physiologically active hormone itself but a precursor that the body converts into active hormones downstream.¹ Think of DHEA as crude oil: it has enormous potential energy, but it doesn’t power anything in its raw form. It has to be refined. The refinery is a network of enzymes distributed across tissues throughout the body — most notably in the gonads, adrenal cortex, liver, fat tissue, skin, and brain.

The two primary downstream products of DHEA conversion are testosterone and estrogen — specifically estradiol (E2), the most biologically potent form of estrogen. Which product your body makes more of from DHEA depends on a set of variables that are highly individual and rarely discussed on supplement labels.

The Conversion Pathway

The conversion cascade looks like this:

1. DHEA → DHEA-S (sulfated form, primary storage and transport form)
2. DHEA → Androstenedione (via the enzyme 17β-HSD — an androgen intermediate with some direct activity but primarily a further conversion substrate)
3. Androstenedione → Testosterone (via 17β-HSD in the gonads and peripheral tissues)
4. Testosterone → Estradiol (E2) (via aromatase enzyme — this is where the trap lives)

What this pathway tells you: DHEA is not testosterone. DHEA is not estrogen. DHEA is a raw input that the body routes toward whichever downstream hormones its enzyme activity favors — and that enzyme activity is governed by age, sex, body composition, genetics, and stress load.

Key Insight: If you have high aromatase enzyme activity — which correlates strongly with body fat percentage, age, and certain genetic profiles — supplementing DHEA doesn’t reliably raise testosterone. It raises estradiol. That distinction is everything.

Replacement vs. Pharmacological Dosing: A Critical Distinction

Not all DHEA doses are created equal — and the difference between a physiological replacement dose and a pharmacological dose is where most unsupervised supplementation goes wrong.

Think of it this way: if your DHEA-S blood levels are those of a 65-year-old and you supplement to restore them to the range of a healthy 30-year-old, you are replacing a deficit. You are giving the factory back its raw material supply. The research supporting DHEA replacement in individuals with genuine deficiency — including the landmark Arlt et al. (1999) study in women with adrenal insufficiency — shows real, meaningful improvements in well-being, fatigue, libido, and mood.¹

But if you take a dose that pushes DHEA-S levels above youthful physiological ranges — into what would be pharmacological territory — you are not restoring balance. You are flooding the enzyme system with far more substrate than it was designed to process in balance, and the downstream consequences are unpredictable and highly individual.

• Replacement range doses (typically 25–50mg/day for most adults, under medical supervision with blood work) aim to restore age-appropriate serum DHEA-S levels.
• Pharmacological doses (100mg+ without testing or monitoring) push substrate levels beyond physiological norms and dramatically increase the conversion pressure on downstream pathways — including aromatization.

Replacement restores the supply line. Pharmacological dosing overwhelms the factory. They are not the same intervention.

The Aromatase Trap: When More Androgen Becomes More Estrogen

This is where the conversation shifts from informational to genuinely important for anyone considering DHEA supplementation — and for anyone trying to understand why their hormone optimization attempts haven’t delivered the results they expected.

The trap has a name: substrate-driven aromatization. And once you understand the mechanism, you’ll recognize it in a wide range of scenarios that go well beyond DHEA.

Think of aromatase as a conversion factory with a fixed number of production lines. At low substrate levels, it converts a modest percentage of available androgen to estrogen — a normal, healthy balance. But as you flood the system with more androgen substrate — either through natural production, pharmaceutical testosterone, or DHEA supplementation — the factory runs more production lines. More substrate in means more estradiol out. This is substrate-driven aromatization.

The Scenario: Why More Androgen Input Often Means More Estrogen

Consider a man in his late forties who reads about DHEA’s role in the TRIIM trial and decides to supplement without testing his conversion profile. He is carrying extra weight around the abdomen — a common reality for men in this age range. Adipose tissue is aromatase-dense. He has a well-stocked factory.

He adds a daily DHEA supplement, pushing androgen substrate into a system with high aromatase activity. The conversion cascade runs: DHEA converts to androstenedione, androstenedione converts to testosterone, and then — instead of that testosterone accumulating — the aromatase-heavy fat tissue converts a significant portion of it straight to estradiol.

The net result: his testosterone may rise modestly. His estradiol rises more significantly. The ratio — the critical T:E2 balance — tips in the wrong direction.

The symptoms of elevated estradiol in men are not abstract — they’re reported and recognizable: water retention, breast tissue sensitivity (gynecomastia in severe cases), emotional volatility, reduced libido, fatigue, and paradoxically blunted muscle-building response despite elevated androgen substrate. This is not what anyone who starts supplementing DHEA for vitality and recovery is expecting.

The Skeptic’s Question: Is DHEA supplementation raising your testosterone — or is it primarily driving up your estradiol? You cannot know without baseline blood work and follow-up testing. Anyone selling you DHEA without mentioning this question is selling you half the story.

The Same Trap in Other Contexts

Substrate-driven aromatization isn’t unique to DHEA. The same mechanism operates in any scenario where androgenic substrate is elevated above the body’s baseline:

• Testosterone replacement therapy (TRT) without aromatase management: A common reason why men on TRT report initial gains followed by a plateau — and why managing E2 with an aromatase inhibitor (AI) is standard clinical practice in well-managed TRT protocols.
• Androstenedione supplementation — briefly popular in the 1990s after Mark McGwire mentioned it — failed largely because of this mechanism. The majority of supplemented androstenedione converted to estrone rather than testosterone in most users.
• High-dose testosterone cycles without estrogen management: The “why am I holding water and feeling emotional at 500mg/week” question has the same answer every time.

The common thread: the aromatase enzyme does not care about your intentions. It responds to substrate availability. Give it more androgens, and — if aromatase activity is high — it will convert more androgens. The feedback signal that would normally slow this process down (high estradiol suppressing LH and GnRH) gets disrupted the moment you introduce exogenous substrate. Which brings us to the feedback loop failure.

The Feedback Loop Failure: When the Internal Thermostat Breaks

Your endocrine system is a closed-loop control system — think of it as a sophisticated thermostat that monitors hormone levels and adjusts production up or down to maintain balance. Under normal circumstances, this system is elegant and self-correcting.

The central control loop — the hypothalamic-pituitary-gonadal (HPG) axis — works like this: the hypothalamus releases GnRH, which signals the pituitary to release LH and FSH, which signal the gonads to produce testosterone. When testosterone (and estradiol, which is aromatized from it) reaches adequate levels, they feed back to the hypothalamus and pituitary to turn down the signal. The thermostat regulates the room temperature.

What Exogenous Precursors Do to the Thermostat

When you introduce exogenous DHEA — or any exogenous androgen precursor — you are bypassing the thermostat’s input sensor. You’re adding heat to the room through a source the thermostat can’t measure.

The body’s production of endogenous DHEA is regulated by ACTH from the pituitary. But DHEA from a supplement doesn’t feed back to turn down ACTH in the same controlled way. The exogenous substrate floods the conversion pathway without the HPG axis being able to proportionally reduce its own output to compensate. The result is an unchecked elevation of downstream metabolites — including estradiol — that can overshoot the physiological range before the system can rebalance.

This is why the downstream side effects of unsupervised DHEA supplementation — particularly at pharmacological doses — are not rare edge cases. They are predictable consequences of introducing raw material into a conversion system without managing the thermostat.

The Side Effect Profile: What Unchecked Aromatization Looks Like

When estradiol rises unchecked relative to testosterone, the downstream effects cluster into recognizable patterns:

• Water and sodium retention: Estradiol stimulates aldosterone activity and promotes water retention. The body holds more fluid — particularly around the abdomen and face. The scale moves, but not in the direction anyone wanted.
• Emotional dysregulation: Estradiol has significant neuroactive effects. An abrupt or disproportionate rise — particularly relative to a declining testosterone baseline — is associated with irritability, anxiety, emotional reactivity, and in some individuals, depressive episodes. This is not a personality change; it is a biochemical state change.
• Libido paradox: Counterintuitively, high estradiol in men suppresses libido — despite the common assumption that more androgen substrate means more sexual drive. The T:E2 ratio matters more than absolute estradiol levels.
• Blunted anabolic response: High estradiol relative to free testosterone impairs the androgen receptor signaling that drives muscle protein synthesis. You can have adequate testosterone on paper while the T:E2 imbalance blunts the cellular response.
• Breast tissue sensitivity: In susceptible individuals, chronically elevated estradiol promotes glandular tissue growth — gynecomastia. This is not a myth or a rare event; it is a known clinical consequence of unchecked aromatization in men.

None of these effects are inevitable with DHEA supplementation. But they are the predictable downstream consequences of flooding a high-aromatase system with androgenic substrate without monitoring or managing the conversion. And they represent the gap between “DHEA is the body’s most abundant hormone and declining levels should be restored” (true) and “therefore supplement freely without testing” (dangerous oversimplification).

The problem isn’t DHEA. The problem is flooding a system you haven’t mapped — and expecting a specific output from a conversion process you don’t control.

Your Conversion Profile: Why Individual Biology Changes Everything

The TRIIM trial used medically supervised DHEA dosing with active monitoring of downstream hormones. That detail matters enormously — and it’s the model that should guide anyone considering DHEA as part of a longevity or hormone optimization strategy.

But what actually determines your conversion profile — whether exogenous DHEA flows preferentially toward testosterone or estradiol in your system? Several interacting variables:

Body Composition and Adipose Distribution

Adipose tissue is the body’s primary aromatase reservoir outside the gonads. Higher body fat percentage — particularly visceral and subcutaneous abdominal fat — directly correlates with higher peripheral aromatase activity. This is not a fitness judgment; it is an enzyme distribution fact.

The practical implication: two individuals with identical DHEA-S levels and identical supplementation doses will have different downstream conversion profiles if one carries more adipose tissue than the other. The higher-body-fat individual will aromatize a larger proportion of that substrate to estradiol.

Age and Enzymatic Shifts

Aromatase activity increases with age, independently of body composition changes. The combination of declining DHEA production, declining testosterone production, and increasing aromatase activity in the 40s and 50s creates a convergence that explains much of the symptomatic hormonal shift men and women experience in midlife — even without any supplementation.

When you add exogenous DHEA into a system that is older, has higher aromatase activity, and is already trending toward estradiol dominance, you are not simply restoring youthful hormone levels. You are adding substrate to a system whose conversion machinery has aged differently than its supply lines.

Genetic Variation in CYP19A1

The gene encoding aromatase — CYP19A1 — has known polymorphisms that produce meaningful variation in aromatase enzyme activity between individuals. Some people are genetically fast aromatizers; others are slow. This variation is not currently captured by standard hormone panels, but it is a real contributor to why two people on identical DHEA protocols can have dramatically different estradiol responses.

Stress Load and Cortisol Status

Cortisol — the body’s primary stress hormone — competes with DHEA for the same upstream precursor (pregnenolone) and modulates the activity of several enzymes in the steroidogenesis cascade. Chronically elevated cortisol doesn’t just suppress endogenous DHEA production; it also shifts the downstream conversion environment in ways that can favor estrogen-dominant outcomes.

For the person who adds DHEA to manage adrenopause while under significant chronic stress — work pressure, poor sleep, relationship strain, over-training — the hormonal environment is already compromised. The DHEA substrate is entering a system that is not primed to convert it optimally.

The Practical Takeaway: Before supplementing DHEA, establish your baseline. Test DHEA-S, free testosterone, total testosterone, estradiol (E2), and SHBG. Retest 6–8 weeks after any dose introduction. Your conversion profile cannot be assumed — it must be measured.

Moving from ‘More Is Better’ to ‘Balance Is Required’

The premise of DHEA as a longevity and vitality tool is not hype. The evidence for DHEA replacement in individuals with genuine adrenal insufficiency is solid.¹ The rationale for its inclusion in the TRIIM protocol as a cortisol buffer during rhGH administration is mechanistically sound. The association between declining DHEA levels and markers of biological aging is real and consistent across the research literature.

But the leap from “DHEA declines with age and declining levels are associated with poor outcomes” to “therefore supplement freely” skips over the most important chapter in the story — the one about what your body actually does with the raw material you give it.

The aromatase trap is not a rare edge case. It is the predictable consequence of misunderstanding DHEA’s role as a prohormone, ignoring individual conversion profiles, and treating a complex feedback-regulated system as if it responds linearly to substrate input. More raw material does not equal more of the hormone you want. It equals more of whichever hormone your enzyme activity profile favors. For many people in their forties and fifties — particularly those with higher body fat, elevated stress, or high aromatase genetics — that means more estradiol.

The path forward is precision, not volume. Test first. Dose based on where your levels actually are. Monitor downstream conversion. Understand that DHEA optimization is a process of calibrating your internal chemistry, not flooding it.

In Part 3 of this series, we take everything we’ve covered — the TRIIM blueprint, the DHEA pipeline, and the aromatization reality — and build the framework for how to approach biological age optimization at the individual level, with a clear-eyed assessment of what monitoring, lifestyle intervention, and targeted supplementation can and cannot achieve.

See Also: The TRIIM Trial Blueprint: Can We Actually Reverse Biological Age? (Part 1 of 3)

See Also: Metabolic Endotoxemia — The Silent Inflammation Blocking Your Fitness Gains

See Also: Battling Stress — How Cortisol Affects Your Testosterone and Recovery (Coming Soon)

Actionable Takeaways: Moving from ‘More’ to ‘Balanced’

Whether you’re a man in your mid-forties starting to feel the hormonal shift, a woman navigating post-menopausal adrenal dependency, or simply someone who wants to understand the landscape before any intervention — here is what the evidence supports:

Step 1: Test Before You Supplement

• Minimum baseline panel: DHEA-S, total testosterone, free testosterone, estradiol (E2), SHBG (sex hormone binding globulin), and cortisol (morning, fasting).
• These numbers establish your conversion profile baseline and tell you whether you have an actual deficiency or a functional balance issue. You cannot manage what you haven’t measured.
• Request specific estradiol testing with a sensitive assay (LC/MS-MS method) — standard immunoassay E2 tests are less accurate in men and post-menopausal women at lower E2 ranges.

Step 2: Reduce Aromatase Activity Through Body Composition

• Before introducing any exogenous androgen substrate, reducing adipose tissue — particularly visceral fat — directly reduces peripheral aromatase activity. This is the most controllable, medication-free lever you have.
• Progressive resistance training improves body composition and enhances androgen receptor sensitivity simultaneously — addressing both the substrate side and the receptor response side of the equation.

Step 3: Address the Cortisol-DHEA Ratio Through Lifestyle First

• Chronic cortisol elevation suppresses endogenous DHEA and shifts the downstream conversion environment. Prioritizing sleep quality (7–9 hours, consistent schedule), stress management practices, and training periodization addresses the root cause of the ratio imbalance before resorting to supplementation.
• Adaptogenic herbs with emerging research support — ashwagandha (KSM-66 extract at 300–600mg/day) and phosphatidylserine (400–800mg/day) — have shown some evidence for cortisol modulation, though the research is not yet definitive enough to call these established interventions.

Step 4: If Supplementing DHEA, Start Low and Retest

• Evidence-supported starting doses for most adults in the physiological replacement range: 25mg/day for men, 10–25mg/day for women. These are replacement-range doses, not pharmacological ones.
• Retest at 6–8 weeks: DHEA-S, testosterone, and estradiol. If estradiol has risen disproportionately relative to testosterone, you are aromatizing aggressively and the dose needs adjustment — not escalation.
• DHEA supplementation should be pursued under medical supervision, not self-directed based on general guidelines. Individual conversion profiles are too variable for one-size-fits-all dosing.

Step 5: Understand the T:E2 Ratio as the Target Metric

• For men, a testosterone-to-estradiol ratio (using free testosterone in pg/mL and E2 in pg/mL) in the range of approximately 10:1 is often cited as a general functional target, though optimal ranges are individual. Absolute levels matter; ratio matters more.
• Symptoms of imbalance — water retention, emotional volatility, reduced libido, breast sensitivity, blunted body composition response — are clinical signals that the ratio has shifted, regardless of what the individual numbers look like in isolation.

Part 1 of 3: The Biological Age Series: TRIIM Trial, Can we reverse aging?

Part 3 of 3: This Biological Age Series: DIM, Estrogen, and Regulation

Research & References

¹ Arlt, W., Callies, F., van Vlijmen, J. C., Koehler, I., Reincke, M., Bidlingmaier, M., … & Allolio, B. (1999). Dehydroepiandrosterone replacement in women with adrenal insufficiency. New England Journal of Medicine, 341(14), 1013–1020. — A landmark randomized controlled trial demonstrating that DHEA replacement in women with confirmed adrenal insufficiency produced significant, measurable improvements in well-being, fatigue, mood, and libido relative to placebo, establishing the clinical evidence base for DHEA as a replacement therapy in deficiency states.

Kyle Hansen Fitness  |  Science-driven health and nutrition insights for stronger bodies and longer lives.